Biodesix announces presentation of new nodify xl2® data at aabip conference highlighting increased proportion of biopsies diagnosing cancer

Boulder, colo.--(business wire)---- $bdsx #patientsfirst--biodesix, inc. (nasdaq: bdsx), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that a new analysis from the post-market, prospective, real-world oracle study (an observational registry study to evaluate the performance of the nodify xl2 test nct03766958) will be presented at the 6th annual conference of the american association for bronchology and interventional pulmonology (aabip). the data will be presented by p.
BDSX Ratings Summary
BDSX Quant Ranking